Drug Profile
Mipomersen - Kastle Therapeutics
Alternative Names: ISIS-301012; Kynamro; Mipomersen sodium - Kastle TherapeuticsLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Genzyme Corporation; Isis Pharmaceuticals; Kastle Therapeutics
- Class Antihyperlipidaemics; Antisense oligonucleotides; Oligodeoxyribonucleotides
- Mechanism of Action Apolipoprotein B-100 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperlipoproteinaemia type IIa
- Discontinued Atherosclerosis
Most Recent Events
- 15 Apr 2021 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
- 15 Apr 2021 Discontinued - Phase-III for Hyperlipoproteinaemia type IIa (Adjunctive treatment) in Taiwan, Singapore, South Africa, South Africa, Brazil (SC)
- 15 Apr 2021 Discontinued - Phase-III for Hyperlipoproteinaemia type IIa (Adjunctive treatment) in United Kingdom, Ukraine, Turkey, Taiwan, Sweden, Spain, South Africa, Russia, Poland, Norway, New Zealand, Netherlands, Netherlands, South Korea, Malaysia, Italy, Israel, Hungary, India, Hong Kong, Greece, Germany, Denmark, Czech Republic, Croatia, Canada, Brazil, Belgium, Australia, Argentina, USA (SC)